A state of operational tolerance has been described in kidney transplant patients who deliberately decided to stop immunosuppression. 1 These patients displayed a stable graft function after complete drug withdrawal for longer than 1 year. In 2007, Brouard et al 2 performed the first study in kidney transplant patients aimed at identifying biomarkers of tolerance from peripheral blood samples, defining a "tolerant fingerprint" of 49 genes. The same group reported later that tolerant recipients exhibited a significant increase in absolute numbers and frequency of total B cells, particularly activated memory and early memory B cells. 3 In the same year, 2 independent multicenter studies, the European Indices of Tolerance study 4 and the USA Immune Tolerance Network study 5 reported and validated a B-cell signature in 11 and 19 kidney transplant tolerant patients, respectively. In both studies, an overexpression of multiple B cell-related genes and maintenance of peripheral blood B cell numbers and percentages in tolerant recipients were observed. Moreover, in the Immune Tolerance Network study, an upregulation of CD20 mRNA in sediment cells from urine and elevated numbers of peripheral blood naive and transitional B cells in tolerant participants, compared with those receiving immunosuppression, were also observed. 5 In 2012, another group reported that tolerant recipients exhibited similar numbers and percentages of circulating total B cells, naive, memory, and regulatory B cells than healthy individuals, as well as preserved B-cell receptor (BCR) repertoire. In addition, they demonstrated that tolerant recipients displayed a conserved capacity to activate CD40/STAT3 signalling pathway in regulatory B cells. 6 In 2014, Brouard's group showed that B cells from tolerant recipients exhibited a defective expression of factors involved in the differentiation into plasma cells, and the B cells were more prone to cell death by apoptosis compared with patients with stable graft function. 7 Finally, in 2015, the same group showed that tolerant recipient exhibit a higher number of Granzyme B + B cells compared with healthy volunteers and stable recipients. 8 They showed that Granzyme B + B cells were able to inhibit CD25 − CD4 + T cell responses through a proapoptotic mechanism. 8 CD40 and BCR ligation on B cells are key events in their function, and T cells contribute to both. The predominance of the BCR signalling alone favors apoptosis, 9 whereas the predominance in the CD40 ligation favors cell survival 9 and IL-10 secretion. 10 The combination of both signals favors cell activation, differentiation, and antibody production 11 ; however, it has been reported that IL-10 production by CD27 − B cells is reduced when CD40 and BCR are triggered together compared with CD27 − B cells activated only through CD40-CD40L interaction. 10 In this study, we hypothesized that altered BCR/CD40 signalling is linked to increased IL-10 production observed in tolerant patients. The B cell responses from a cohort of tolerant renal transplant recipients were compared with age/ sex-matched healthy volunteers. The data presented in our study demonstrated that B cells from tolerant patients exhibited an imbalance in CD40/BCR signalling compared with healthy controls, suggesting that these differences may contribute their increased IL-10 production and to the long-term graft survival observed in tolerant patients.
MATERIALS AND METHODS

Patients
Patient samples were donated from the Genetic Analysis & Monitoring of Biomarker of Immunological Tolerance study, approved by the Institute of Child Health/Great Ormond Street Hospital Research Ethics Committee 09/H0713/12. All experiments were performed in accordance with the approved guidelines and regulations. Samples were processed and analyzed in a blinded fashion after informed consent was obtained from all subjects. Of patients from the Genetic Analysis & Monitoring of Biomarker of Immunological Tolerance study, the following ones have been used in this project: Tolerant (n = 16): Functionally stable kidney transplant recipients despite having stopped all their immunosuppression for longer than 1 year with a serum creatinine CRT < 160 μmol/L and less than 10% rise in the last 12 months. End stage renal failure causes have been summarized in Table 1 . Healthy control (n = 11): Healthy volunteers were age-and sex-matched to tolerant patients. Patient characteristics are described in Table 1 .
Sample Collection
Peripheral Blood Mononuclear Cells (PBMCs) from patients and healthy controls were isolated from peripheral blood by Ficoll-Hypaque (PAA) density gradient centrifugation. Cells were resuspended in 10% dimethyl sulfoxide (Sigma-Aldrich)-AB human serum (BioWest) and frozen immediately at −80°C. After 24 hours, cells were transferred into liquid nitrogen where they were kept until use. Cell counts for each patient were obtained from their respective full blood count test (National Health System, UK). Serum samples were obtained after centrifugation of coagulated peripheral blood samples (2000 rpm/20 min at room temperature), stored at −80°C and kept until use.
B-Cell Phenotypic Studies
PBMC samples were thawed from liquid nitrogen on the same day as the staining, and 3 Â 10 6 PBMCs were used to study B cell phenotype. PBMCs were stained with live/dead (Invitrogen), anti-IgM-PercP-Cy5.5 (BD), anti-IgD-PE (BD), anti-CD19-AlexaFluor780, anti-CD20-AlexaFluor700, anti-CD27-APC, anti-CD24-FITC, anti-CD38-PECy7 (all eBioscience) for 30 minutes at 4°C. Cells were acquired on LSRFortessa (BD). Data were acquired until at least 5000 events in the B-cell subset were counted. All flow cytometry data were analyzed using FlowJo (Tree Star, Inc. Ashland, OR 97520 USA) or DIVA software (BD). ) from patient samples were cultured with or without 0.5 Â 10 5 plate bound CD40L-transfected and nontransfected mouse L-fibroblast cells (X-ray irradiated for 30 minutes, 9045 cGy) for 72 hours. After 3 days, expression of CD86-FITC and CD25-PE (all eBioscience) and intracellular IL-10-PE (BD) and TNF-α (eBioscience) were measured in CD20 + B cells. Supernatants were collected and stored at −80°C to subsequently measure cytokines by enzymelinked immunosorbent assay. Methods for intracellular staining, enzyme-linked immunosorbent assay and experiments in B-cell subsets isolated from healthy leukocytes retained in filtering cones and patient samples can be found in the SDC (http://links.lww.com/TP/B310).
T-Cell Activation
CD4
+ T cells were isolated using CD4 + T cell Isolation Kit II, human (Miltenyi Biotec). Cells were activated with αCD3/ CD28 beads (1:2 ratio) (Invitrogen) for 8 and 48 hours. After 8 hours, cells were stained with CD4-FITC (eBioscience) and CD40L-PE (eBioscience) for 30 minutes at 4°C. Cytokines in the supernatants were measured using Cytometric Beads Array human Th1/Th2/Th17 kit (BD) For IL-2, the sensitivity of the kit was 2.6 pg/mL, and the standard curve range was from 2.6 to 5000 pg/mL. For IL-4, the sensitivity of the kit was 4.9 pg/mL, and the standard curve range was from 4.9 to 5000 pg/mL. Cells and beads were acquired on LSRFortessa (BD).
BCR Activation Measured on Patient's PBMCs
PBMCs from patients and healthy controls were thawed and rested overnight in media supplemented with IL-2 (100 ng/mL, R&D) at 37°C, 5% CO 2. The next day, cells were stained with CD20-Pacific Blue (eBioscience), CD27-APC (eBioscience), CD24-PE (eBioscience), CD38-PE-Cy7 (eBioscience), and Live/Dead dye (Invitrogen) for 20 minutes at 37°C, 5% CO 2 . After the staining, 1 Â 10 6 PBMCs were placed in 5 mL polystyrene tubes, cells were washed, rested for 30 minutes at 37°C, 5% CO 2 and activated with antiIgM (20 μg/mL)/anti-IgG (20 μg/mL) (Southern Biotech) for 0, 10, and 30 minutes and with phorbol-12-myristate-13-acetate (PMA) (0.1 μM, Sigma) for 10 minutes at 37°C. Cells were fixed with BD Cytofix buffer (BD) for 10 minutes at 37°C, permeabilized with BD Phosflow Perm Buffer III (BD) for 30 minutes on ice and stained with anti-extracellular signal-regulated kinases 1 and 2 (ERK1/2) (pT202/pY204)-AlexaFluor488 (BD) for 30 minutes at 4°C. Cells were acquired on LSRFortessa (BD).
Detection of IgG1 Serum Levels
Serum IgG1 levels were measured with the Human Immunoglobulin Isotyping Magnetic Bead Panel Milliplex Map Kit (Millipore) in healthy volunteers and tolerant recipients.
Statistical Analysis
All columns in graphs represent the mean and standard error of mean. Nonparametric Mann-Whitney U test was used to analyze phenotypic flow cytometry data in patient and healthy control samples. Two-way repeated measurement analysis of variance test with Sidak multiple comparisons was used to evaluate differences between nonactivated and activated samples. We defined significance as **** P < 0.0001, *** P < 0.001, ** P < 0.01, and * P < 0.05. We performed data tables, statistical analysis results, and graphs using Prism 6 (1992-2012 GraphPad Software, Inc, La Jolla, CA). Previous studies, from us and others, have established that the percentages of total B cells in tolerant renal transplant patients were similar to healthy volunteers. 3, 5, 6 This was confirmed in a new cohort of tolerant recipients (Table 1) in whom similar percentages of total, memory, naive, and transitional B cells between healthy controls and tolerant recipients were observed ( Figure 1A and Fig. S1 , SDC, http://links.lww.com/TP/B310).
RESULTS
IL-10 production has been shown to be the main regulatory mechanism for transitional B cells in autoimmunity, 12 graft-versus-host disease, 13 as well as transplantation, 5, 7, 14 therefore, the production of this cytokine was studied in the new cohort of tolerant patients. B cells were stimulated via CD40 molecules by using CD40L-expressing L cells, and as control nontransfected L cells. CD40 stimulation of B cells, in healthy volunteers-sorted B-cell subsets isolated from peripheral blood cones, preferentially induced IL-10 production by transitional B cells, whereas the TLR9 agonist CpG, used as positive control, led to IL-10 production by all the different B-cell subsets (Fig. S2 , SDC, http://links.lww.com/TP/B310). After confirming that CD40-ligation was inducing IL-10 mainly in transitional B cells, the production of IL-10 was then compared in B cells between healthy volunteers and tolerant patients. The percentage of IL-10 + B cells and the levels of IL-10 in the supernatants were significantly higher in samples from tolerant recipients compared with healthy volunteers, whereas no differences in the levels of TNF-α between the 2 groups was observed ( Figure 1B) . To confirm that the difference in IL-10 production between tolerant patients and healthy individuals was not due to differences in the susceptibility of B cells to be activated, the expression of CD25 and CD86 molecules by B cells after CD40-ligation was analyzed. Similar upregulation of both molecules was observed in the 2 cohorts of individuals ( Figure 1C) .
T cells are key in the activation of B cells, and the engagement of CD40 expressed by B cells by CD40L on T cells is essential in inducing IL-10 production. 12 Therefore, we measured the expression of CD40L on CD4 + T cells from tolerant patients and healthy controls. We observed that the levels of expression of CD40L, although similar between the 2 cohorts of individuals before T cell activation, were higher 8 hours postactivation with CD3/CD28 beads, in T cells from tolerant patients, suggesting that T cells from tolerant recipients have an advantage in engaging CD40 molecules on B cells compared with healthy volunteers ( Figure 1D) .
B Cells From Tolerant Recipients Have Decreased BCR Signalling Compared With Healthy Volunteers
We have shown so far that tolerant patients exhibited increased IL-10 production by B cells and that CD40L expression is higher in T cells compared with healthy volunteers.
Another function of B cells that may be relevant for the maintenance of a tolerant state is their capacity to bind antigen via the BCR and then present it to T cells. 15 At the same time, it has been shown previously that BCR engagement leads to the maturation and activation of B cells via the mitogen-activated protein kinase kinase-ERK signalling pathway. 16 Therefore, the phosphorylation of ERK was evaluated by stimulating B cells with anti-IgG/anti-IgM (Figures 2A and B) . Activation + Tcells from healthy HC = 6 and Tol = 7 patients were measured after 8 hours of activation with CD3/CD28 beads (1:2 ratio). Two-way RM ANOVA test with a Sidak multiple comparisons test was used. For all statistical tests **** P < 0.0001, *** P < 0.001, ** P < 0.01, and * P < 0.05 were considered significant. RM ANOVA, repeated measurement analysis of variance.
with PMA, that bypasses the BCR, was used as a positive control ( Figure 2B) . The results are presented as the differences in phosphorylation between samples activated via the BCR for 10 minutes and nonactivated (ΔERK) ( Figure 2C ). All B-cell subsets from tolerant recipients exhibited reduced ΔERK compared with healthy controls (Figure 2D ), whereas no differences in ΔERK were observed after PMA activation ( Figure 2E) , suggesting that the reduction in ERK phosphorylation in the B cells from tolerant recipients was specific to the BCR stimulation. CD40-mediated IL-10 production by CD27 − B cells was inhibited with simultaneous CD40 and BCR stimulation. 10 As predicted, IL-10 production was reduced in transitional B cells from healthy individuals when B cells were stimulated via CD40 and BCR compared to ligation of CD40 alone ( Figure 2F and Fig. S3 , SDC, http://links.lww. com/TP/B310). In addition, we observed that the combination of CD40 and BCR stimulation resulted in downregulation of ERK-phosphorylation compared with BCR stimulation alone (Fig. S4 , SDC, http://links.lww.com/TP/B310). Having shown that the effect on IL-10 release was mainly observed in the transitional population, IL-10 production by transitional B cells in response to ligation of CD40 and BCR was compared between healthy individuals and tolerant patients. We found that, whereas IL-10 production after CD40 and BCR stimulation was decreased in transitional B cells from healthy volunteers, it was maintained in transitional B cells from tolerant recipients ( Figure 2G ). These results suggest that the reduced BCR signalling present in B cells from tolerant recipients allowed sustained CD40-mediated IL-10 production after dual activation.
It has been described that mice deficient for Ras guanyl nucleotide exchange factor 3 (Rasgrp3 −/− ), exhibit reduced ERK phosphorylation after BCR activation and lower titters of IgG1 in their sera, 17 suggesting that reduction in the BCR-ERK signalling plays a role in the humoral response, skewing it to IgG subclasses with lower complement binding. Furthermore, IL-2 and IL-4 present during the class-switch also affect the production of IgG1. 18, 19 Therefore, the production of these 2 cytokines by CD4 + T cells from patients and healthy volunteers was measured after T-cell receptor activation. The analysis of these cytokines after 48 hours of culture revealed that the levels of IL-2 and IL-4 were lower in T cells from tolerant patients compared with healthy controls ( Figure 2H ). In accordance with reduced BCR signalling and reduced levels of IL-2 and IL-4, lower levels of IgG1 were found in the serum of tolerant recipients compared to healthy volunteers ( Figure 2I ).
DISCUSSION
Here, we describe for the first time that tolerant patients exhibit higher percentages of IL-10-producing B cells after CD40 activation and reduced BCR signalling compared with healthy controls. We also demonstrated that the reduction in BCR signalling favored IL-10 production in the transitional B-cell population of tolerant recipients. Furthermore, the reduced ERK activation together with the reduced IL-2 and IL-4 production by T cells may contribute to the low IgG1 levels observed in the serum (Fig. S5 , SDC, http://links.lww.com/TP/B310).
The percentages of B cells and the expression of B cellrelated genes have been previously compared between tolerant patients and either healthy individuals or other groups of patients under immunosuppressive therapy. [3] [4] [5] [6] Newell et al 5 reported for the first time that following stimulation with PMA + Ionomycin, transitional B cells from tolerant individuals expressed higher percentages of IL-10 relative to stable patients or healthy controls. Although their differences were significant, they recognized that the overall percentages of IL-10-producing B cells were extremely low, with many samples containing no IL-10-producing cells, and with a large overlap in IL-10 expression between groups, suggesting that PMA + Ionomycin may not have been the optimal stimulus to measure IL-10-producing B cells within PBMCs. On the other hand, data from Silva et al, 6 using specific CD40 activation, showed higher STAT-3 phosphorylation in regulatory B cells from 5 tolerant patients compared with patients with chronic rejection, indicating that the IL-10 signalling pathway was activated in tolerant recipients. More recently, Chesneau et al 7 demonstrated higher IL-10 production by B cells from tolerant kidney transplant patients compared with healthy volunteers and stable recipient after a combination of anti-IgG/ IgM/IgA, soluble CD40L, CpG, and IL-2. However, the addition of CpG in the latter study complicated the interpretation of the results, as CpG induced IL-10 production by a different signalling pathway compared with CD40 and by different B cell subsets (Fig. S2 , SDC, http://links.lww.com/TP/B310). Here, we showed that CD40L activation induces IL-10 production preferentially by transitional B cells and that IL-10 production was higher in transitional B cells from tolerant patients after dual-BCR/CD40L activation compared with healthy volunteers. Because these activations targeted mainly the transitional B cell population, it is difficult to compare the IL-10 production between tolerant recipients and patients under immunosuppressive treatment because the latter patients exhibited extremely low percentages of transitional B cells (data not shown).
IL-10 is a well-known anti-inflammatory cytokine. The production of IL-10 by B cells has been shown to inhibit T cell proliferation, 13 cytokine production, 12 and promote regulatory T-cell differentiation. 20 Furthermore, IL-10 also attenuates the antigen presentation capacity of B cells by downregulating the expression of CD86 on their surface in mouse 21 and human. 14 In human diseases, IL-10 production has been proposed as the main regulatory mechanism used by B cells in lupus, 12 arthritis, 20 graft-versus-host disease, 13 and transplantation. 22 The production of IL-10 in tolerant recipients may indicate that in these patients, it may contribute to the maintenance of a stable graft function in the absence of any immunosuppressive therapy.
Along with more IL-10 production, B cells from tolerant recipients also exhibited a reduced BCR signalling. Mice with impaired BCR signalling exhibited lower titters of IgG1 in the sera compared with wild-type mice, 17 suggesting that reduced BCR signalling affects the Ig class-switch to IgG1. Furthermore, Chesneau et al 7 showed that B cells from tolerant recipients exhibit a down-regulation of B cell differentiation genes. Accordingly, we observed in tolerant patient's lower levels of IgG1 in the sera and lower secretion of the cytokines that contribute to the IgG class switching, IL-2 and IL-4 compared with healthy volunteers. More specifically, IL-4 has been shown to induce the production of the IgG subclasses IgG1, IgG2, and IgG3, whereas IL-2 promotes IgG1 and IgG3 release. 18, 19 In addition, IL-2 produced by T cells is required for ERK1/2-mediated differentiation of human naive nontransfected or CD40L-transfected L cells, with or without BCR activation for 3 days. H, IL-2 and IL-4 production from isolated CD4 + T cells of HC = 6 and Tol = 7 were measured after 48 hours of activation with CD3/CD28 beads (1:2 ratio). Detection limit for IL-2 and IL-4 were 2.6 and 4.9 pg/mL, respectively. I, Levels of IgG1 were measured in the sera from HC and Tol patients. Mann-Whitney U test and 2-way RM ANOVA test with a Sidak multiple comparisons test were used, **** P < 0.0001, *** P < 0.001, ** P < 0.01 and * P < 0.05 were considered significant. B cells into plasma cells 23 and to enhance the effect of IL-10 for the induction of antibody production. 24 Furthermore, it has been shown that low levels of CD40 stimulation induced B-cell activation, whereas high levels of CD40 ligation inhibited Ig production. 11 Our results suggest that the imbalance in the BCR/CD40 signalling pathway and reduced IL-2 and IL-4 secretion by T cells may have prevented the class-switch and further secretion of IgG1 in these patients. In the context of transplantation, reduced levels of IgG1 decreased complementdependent cytotoxicity and Fc-receptors binding; therefore, impairment in the humoral response of these patients could have promoted the tolerant state by reducing antibody-dependent cellular cytotoxicity. 25 Altogether our data suggest that the type of responses produced by B and T cells in tolerant recipients may contribute to long-term stable graft function. Further studies are required to understand whether these responses were developed after transplant, as allograft-specific responses, or whether they are intrinsic or genetically determined in these patients.
